Tisotumab Vedotin-tftv (Tivdak®): A Comprehensive Oncological and Pharmacological Monograph

Introduction and Drug Profile

Overview and Therapeutic Class

Tisotumab vedotin-tftv, marketed under the brand name Tivdak®, represents a significant therapeutic advance in the field of gynecologic oncology.[1] It is a first-in-class, tissue factor (TF)-directed antibody-drug conjugate (ADC) developed to address a critical unmet need in a patient population with limited options.[1] The drug is specifically indicated for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed on or after treatment with chemotherapy.[3] This indication positions Tisotumab vedotin as a pivotal second-line or subsequent therapeutic agent for a disease characterized by a poor prognosis following the failure of initial systemic therapies.[9]

Administered via intravenous infusion, Tisotumab vedotin offers a novel targeted approach that distinguishes it from conventional cytotoxic chemotherapy.[1] Its development and subsequent approval mark a new chapter in the management of advanced cervical cancer, providing a validated therapeutic option that has demonstrated a survival advantage over the previous standard of care.[11] The four-letter, non-meaningful suffix "-tftv" is assigned by the U.S. Food and Drug Administration (FDA) as part of the nonproprietary naming convention for certain biological products. This convention is designed to enhance pharmacovigilance by allowing for the clear differentiation and tracking of Tisotumab vedotin from any potential future biosimilars or related products, ensuring precise attribution of clinical outcomes and adverse events.[1] The FDA's formal designation of Tisotumab vedotin as a "first-in-class" medication is not merely a descriptive term but a regulatory acknowledgment of its unique mechanism of action.[1] This status underscores that the drug introduces a novel therapeutic strategy—the targeting of Tissue Factor with an ADC—for this indication, thereby validating TF as a druggable oncogenic pathway in cervical cancer and justifying the expedited regulatory reviews it received.

Molecular Architecture and Physicochemical Properties

Tisotumab vedotin is a complex biologic therapeutic with an approximate molecular weight of 153 kDa.[13] As an antibody-drug conjugate, its structure is a sophisticated amalgamation of three distinct molecular components, each engineered to perform a specific function in the targeted delivery of a cytotoxic agent.[2]

1. The Antibody (Tisotumab): The targeting moiety is tisotumab, a fully human immunoglobulin G1-kappa (IgG1-κ) monoclonal antibody, also known by the development codes HuMax-TF or TF-011.[3] This antibody is engineered to bind with high specificity and affinity to human tissue factor (TF), a cell-surface protein also referred to as coagulation factor III or CD142.[3] The antibody component is produced using recombinant DNA technology in a mammalian cell line (Chinese Hamster Ovary, CHO), ensuring consistent production and glycosylation patterns.[13]
2. The Cytotoxic Payload (Vedotin): The cytotoxic warhead of the ADC is monomethyl auristatin E (MMAE), a synthetic and highly potent antimitotic agent.[3] MMAE functions as a microtubule-disrupting agent, and it is this component that is ultimately responsible for inducing apoptosis in the target cancer cell.[3]
3. The Linker: The antibody and payload are connected by a protease-cleavable linker. Specifically, it is a valine-citrulline (vc) dipeptide linker, often denoted as vcMMAE.[3] This linker is a critical piece of the ADC's design, engineered to be highly stable in the systemic circulation to prevent premature release of the toxic MMAE. However, it is readily cleaved by lysosomal proteases, such as cathepsin B, which are abundant within the intracellular environment of the target cancer cell following internalization.[4]

A crucial parameter for any ADC is the drug-to-antibody ratio (DAR), which defines the average number of payload molecules attached to each antibody. For Tisotumab vedotin, the DAR is approximately four, meaning each tisotumab molecule carries an average of four molecules of MMAE.[3] This ratio is optimized to balance potent cytotoxicity with an acceptable therapeutic index.

Tisotumab vedotin is supplied for clinical use as a sterile, preservative-free, white to off-white lyophilized cake or powder in a 40 mg single-dose vial, which requires reconstitution and dilution prior to intravenous administration.[4] The drug is identified by a series of unique codes used in regulatory, clinical, and research settings, including DrugBank ID DB16732, CAS Number 1418731-10-8, UNII T41737F88A, and the Anatomical Therapeutic Chemical (ATC) classification code L01FX23.[1]

Preclinical and Clinical Pharmacology

Mechanism of Action and Pharmacodynamics

The therapeutic effect of Tisotumab vedotin is derived from a multi-step, highly targeted process that leverages its composite molecular structure to deliver a potent cytotoxic agent directly to cancer cells. The pharmacodynamic activity is a direct consequence of this targeted delivery and subsequent disruption of essential cellular processes.[3]

Targeting and Binding to Tissue Factor (TF)

The mechanism is initiated when the tisotumab antibody component of the ADC binds with high affinity to Tissue Factor (TF) expressed on the surface of tumor cells.1 TF is a compelling target for cancer therapy due to its differential expression pattern. While its expression is generally low or restricted in healthy adult tissues, it is frequently overexpressed in a wide array of solid tumors, including a high prevalence in cervical cancer.3 This overexpression is not merely a passive marker but is functionally implicated in tumor progression, angiogenesis, metastasis, and is associated with poor clinical outcomes.3 This differential expression creates a therapeutic window, enabling the ADC to selectively recognize and bind to malignant cells while largely sparing normal tissues, a foundational principle for minimizing systemic toxicity.16

Internalization, Trafficking, and Payload Release

Following the binding of Tisotumab vedotin to cell-surface TF, the entire ADC-TF complex is rapidly internalized into the cancer cell through the process of receptor-mediated endocytosis.3 Once inside the cell, the endocytic vesicle containing the complex is trafficked along the endo-lysosomal pathway, ultimately fusing with lysosomes.16 The lysosomal compartment is characterized by a low pH and a high concentration of proteolytic enzymes, such as cathepsins. This specific intracellular environment is key to the ADC's function, as these enzymes recognize and cleave the valine-citrulline linker.4 This proteolytic cleavage is the critical activation step, liberating the cytotoxic payload, MMAE, from the antibody and allowing it to diffuse from the lysosome into the cell's cytoplasm.3

Induction of Cell Cycle Arrest and Apoptosis

Once free within the cytoplasm, MMAE exerts its potent cytotoxic effect. MMAE is a microtubule-disrupting agent that functions by binding to tubulin, the protein subunit of microtubules.3 This binding inhibits the polymerization of tubulin into functional microtubules. As microtubules are essential components of the mitotic spindle required for chromosome segregation during cell division, their disruption leads to a halt in the cell cycle at the G2/M phase.3 Unable to complete mitosis, the cancer cell initiates the intrinsic pathway of apoptosis, or programmed cell death, culminating in its destruction.3

Secondary and Ancillary Mechanisms of Action

In addition to its primary mechanism of direct cytotoxicity, Tisotumab vedotin is understood to exert its anti-tumor effects through several secondary pathways that contribute to its overall efficacy:

• The Bystander Effect: MMAE is a membrane-permeable molecule. After being released inside a TF-positive target cell, it can diffuse through the cell membrane and enter adjacent, neighboring tumor cells.[3] This "bystander killing" is particularly important in tumors with heterogeneous TF expression, as it allows the ADC to eliminate nearby cancer cells that may have low or no TF expression and would otherwise not be targeted directly. This amplifies the therapeutic effect within the tumor microenvironment.
• Immune-Mediated Activity: The tisotumab antibody component is a human IgG1, a subclass known for its ability to engage the host immune system. In vitro studies have demonstrated that Tisotumab vedotin can mediate antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).[3] In these processes, the Fc region of the antibody binds to Fc receptors on immune effector cells (like natural killer cells and macrophages), directing them to recognize and destroy the tumor cell. Furthermore, the drug may promote immunogenic cell death (ICD), a form of apoptosis that results in the release of cellular components that act as signals to recruit and activate the innate immune system, potentially fostering a broader anti-tumor immune response.[3]

The selection of Tissue Factor as the target is fundamental to both the efficacy and the characteristic toxicity profile of Tisotumab vedotin. The therapeutic benefit is derived from the high levels of TF on tumor cells. However, TF is also expressed at lower levels on some normal tissues, including epithelial cells of the skin and eye, and plays a crucial physiological role in the vasculature and coagulation cascade.[3] The binding of Tisotumab vedotin to TF on these non-malignant cells is a direct example of on-target, off-tumor activity. This is the presumed mechanism underlying the most significant and dose-limiting adverse event associated with the drug: ocular toxicity. The ADC likely binds to TF on conjunctival epithelial cells, leading to localized internalization and release of MMAE, causing direct cellular damage, inflammation, and the observed clinical toxicities like conjunctivitis and keratitis.[1] This direct mechanistic link between the drug's intended action and its primary side effect explains the necessity of the rigorous and mandatory eye care regimen required for patients. Similarly, the high incidence of hemorrhage, particularly epistaxis, is likely related to the drug's interaction with TF in the vasculature, which is the primary initiator of the extrinsic coagulation pathway.[1] This duality highlights the therapeutic challenge of maximizing payload delivery to the tumor while mitigating damage to healthy, TF-expressing tissues.

Pharmacokinetics of the Conjugate and Payload

The pharmacokinetic (PK) profile of Tisotumab vedotin is complex, as it involves the characterization of both the intact antibody-drug conjugate and the unconjugated (free) cytotoxic payload, MMAE. A population PK model, developed using data from 399 patients with solid tumors across four clinical trials, provides a comprehensive description of the drug's behavior in the body.[18]

Absorption and Distribution

Tisotumab vedotin is administered exclusively by intravenous infusion. Following a 30-minute infusion of the recommended 2 mg/kg dose, concentrations of the intact ADC peak near the end of the infusion.26 In contrast, the concentration of the released, unconjugated MMAE payload peaks much later, approximately two to three days after the infusion. This delay reflects the time required for the ADC to distribute to tissues, bind to TF, be internalized by cells, and undergo lysosomal cleavage to release the payload.26

The steady-state volume of distribution ($V_{d}$) for the ADC is approximately 7.83 L, indicating that its distribution is largely confined to the plasma and interstitial fluid, which is typical for a large monoclonal antibody-based therapeutic.[26] The central volume of distribution ($V_{c}$) was estimated at 3.10 L in the population PK model.[18] The small molecule payload, MMAE, exhibits moderate plasma protein binding in vitro, ranging from 68% to 82%.[1]

Metabolism

The two components of Tisotumab vedotin are metabolized through distinct pathways. The tisotumab antibody, like other endogenous immunoglobulins, is expected to undergo catabolism into small peptides and individual amino acids that are recycled by the body.26 The unconjugated MMAE payload, once released from the ADC, is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4, based on in vitro studies.1 This metabolic pathway has clinical implications for potential drug-drug interactions with strong CYP3A4 inhibitors or inducers.

Elimination and Excretion

The elimination kinetics of the ADC and the free payload differ significantly. The linear clearance of the intact ADC is low, approximately 1.54 L/day, with a median terminal half-life (t1/2​) of about 4.04 days.26 This relatively long half-life allows for sustained exposure and delivery of the payload to tumor sites between dosing cycles. In contrast, the apparent clearance of unconjugated MMAE is substantially higher, at approximately 45.9 L/day, with a shorter median terminal half-life of 2.56 days.18

A critical pharmacokinetic principle for this ADC is that the elimination of free MMAE appears to be formation rate-limited; that is, its rate of clearance from the body is limited by the rate at which it is slowly released from the circulating ADC reservoir.[26] Consequently, the longer half-life of the ADC is the primary determinant of the duration of systemic exposure to the MMAE payload.

The excretion pathways for Tisotumab vedotin have not been fully characterized. However, data from another MMAE-containing ADC suggest that excretion of MMAE occurs through both feces (approximately 17% of the total administered MMAE) and urine (approximately 6%), primarily as unchanged drug.[1]

Influence of Specific Populations and Covariates

Population PK analyses have shown no clinically significant differences in the pharmacokinetics of Tisotumab vedotin based on patient age (21 to 81 years), race, or mild-to-moderate renal impairment (creatinine clearance 30 to < 90 mL/min).26 The effect of severe renal impairment is unknown, and the drug should be avoided in patients with moderate-to-severe hepatic impairment due to the reliance on hepatic metabolism for MMAE clearance.26 The most influential patient-specific covariate identified in modeling was body weight, which affects both the distribution and elimination of the ADC and MMAE. This finding provides a strong pharmacokinetic rationale for the weight-based (mg/kg) dosing strategy employed in the clinic.18

Immunogenicity

The potential for patients to develop anti-drug antibodies (ADAs) against Tisotumab vedotin is low. Across clinical trials, the incidence of ADA formation was approximately 5.4% to 5.7%.26 The development of neutralizing antibodies, which could potentially interfere with the drug's efficacy, was rare or absent. Importantly, the presence of ADAs did not have a clinically meaningful impact on the pharmacokinetic profiles of either the ADC or unconjugated MMAE.18

Table 1: Summary of Key Pharmacokinetic Parameters for Tisotumab Vedotin and Unconjugated MMAE

Parameter	Tisotumab Vedotin (ADC)	Unconjugated MMAE (Payload)
$C_{max}$ (Mean ± SD)	40.8 ± 8.12 $\mu$g/mL	5.91 ± 4.2 ng/mL
AUC (0-21 days, Mean ± SD)	57.5 ± 13.4 day*$\mu$g/mL	50 ± 35.8 day*ng/mL
Time to $C_{max}$ ($T_{max}$)	Near end of 30-min infusion	~2 to 3 days post-infusion
Median Terminal Half-life ($t_{1/2}$)	4.04 days	2.56 days
Linear Clearance (CL)	1.54 L/day	45.9 L/day
Volume of Distribution ($V_{d}$)	7.83 L (steady state)	2.09 L (apparent)
Plasma Protein Binding	N/A	68% - 82%
Primary Metabolism	Catabolism	CYP3A4

Data derived from studies of patients receiving the recommended dose of 2 mg/kg intravenously every 3 weeks. Sources:.[18]

Clinical Evidence and Efficacy

The clinical development program for Tisotumab vedotin has robustly established its efficacy in a difficult-to-treat patient population, leading to its global regulatory approvals. The evidence is built upon a pivotal Phase 2 trial that supported accelerated approval, followed by a large, randomized Phase 3 trial that confirmed its clinical benefit and superiority over standard-of-care chemotherapy.

The innovaTV 204 Trial: Foundation for Accelerated Approval

The initial robust evidence for the clinical activity of Tisotumab vedotin came from the innovaTV 204 trial (NCT03438396), a pivotal, open-label, single-arm, multicenter Phase 2 study.[2] This trial was designed to evaluate the efficacy and safety of the drug in patients with recurrent or metastatic cervical cancer who had experienced disease progression during or after receiving one or two prior systemic chemotherapy regimens, including at least one platinum-based regimen.[6] The study enrolled 101 patients who received Tisotumab vedotin monotherapy at the now-approved dose of 2 mg/kg every three weeks.[6]

The trial successfully met its primary endpoint, demonstrating a clinically meaningful and durable anti-tumor response in this heavily pretreated population.[33] The key efficacy outcomes, as assessed by an independent review committee (IRC), were as follows:

• Objective Response Rate (ORR): The confirmed ORR was 24% (95% Confidence Interval [CI]: 15.9%–33.3%).[2] This rate of response was considered highly promising in this refractory setting. The responses included a 7% complete response (CR) rate and a 17% partial response (PR) rate, indicating deep responses in a subset of patients.[31]
• Duration of Response (DOR): The responses observed were notably durable. The median DOR was 8.3 months (95% CI: 4.2 months to not reached), suggesting that patients who responded to treatment experienced a sustained clinical benefit.[2]

The compelling combination of a meaningful response rate and the durability of those responses in a patient population with high unmet medical need formed the basis for the U.S. FDA's decision to grant Accelerated Approval for Tisotumab vedotin on September 20, 2021.[1] This regulatory pathway allows for earlier patient access to promising drugs for serious conditions, with the requirement that the clinical benefit be verified in subsequent confirmatory trials.

The innovaTV 301 Trial: Confirmatory Evidence and Superiority over Chemotherapy

The innovaTV 301 trial (NCT04697628) was the large-scale, randomized, active-controlled Phase 3 study designed to serve as the confirmatory trial for Tisotumab vedotin.[11] This global, open-label trial enrolled 502 patients with recurrent or metastatic cervical cancer who had progressed after one or two prior lines of systemic therapy. Patients were randomized on a 1:1 basis to receive either Tisotumab vedotin (2 mg/kg IV every 3 weeks) or the investigator's choice of single-agent chemotherapy, which represented the standard of care at the time and included topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed.[11]

The trial was a resounding success, meeting its primary endpoint of overall survival and all key secondary endpoints. The results demonstrated a statistically significant and clinically meaningful improvement in outcomes for patients treated with Tisotumab vedotin compared to standard chemotherapy.[11]

• Overall Survival (OS) (Primary Endpoint): Treatment with Tisotumab vedotin resulted in a significant extension of life. The median OS was 11.5 months in the Tisotumab vedotin arm compared to 9.5 months in the chemotherapy arm. This represented a 30% reduction in the risk of death for patients receiving the ADC (Hazard Ratio 0.70; 95% CI: 0.54–0.89; p=0.0038).[11] The survival benefit was further supported by the 12-month OS rates, which were 48.7% for the Tisotumab vedotin group versus 35.3% for the chemotherapy group.[12]
• Progression-Free Survival (PFS): Tisotumab vedotin also significantly delayed disease progression. The median PFS was 4.2 months for the ADC arm versus 2.9 months for the chemotherapy arm (HR 0.67; 95% CI: 0.54–0.82; p<0.0001).[11]
• Objective Response Rate (ORR): The rate of tumor shrinkage was more than three times higher with Tisotumab vedotin. The confirmed ORR was 17.8% in the ADC arm compared to just 5.2% in the chemotherapy arm (Odds Ratio 4.0; p<0.0001).[11]

These robust and unequivocally positive results provided the definitive evidence of clinical benefit required by regulatory agencies. The data from innovaTV 301 led the FDA to convert the drug's accelerated approval to a full, traditional approval on April 29, 2024, and served as the primary evidence supporting marketing authorizations in the European Union, Japan, and other regions.[1]

Table 2: Comparative Efficacy Outcomes from the innovaTV 301 Trial (Tisotumab Vedotin vs. Chemotherapy)

Efficacy Endpoint	Tisotumab Vedotin (n=253)	Investigator's Choice Chemotherapy (n=249)	Hazard Ratio (95% CI) or Odds Ratio (95% CI)	p-value
Overall Survival (OS)	11.5 months (9.8, 14.9)	9.5 months (7.9, 10.7)	HR: 0.70 (0.54, 0.89)	0.0038
Progression-Free Survival (PFS)	4.2 months (4.0, 4.4)	2.9 months (2.6, 3.1)	HR: 0.67 (0.54, 0.82)	<0.0001
Objective Response Rate (ORR)	17.8% (13.3, 23.1)	5.2% (2.8, 8.8)	OR: 4.0 (2.1, 7.6)	<0.0001

Data represent median values with 95% confidence intervals for OS and PFS, and percentages with 95% confidence intervals for ORR. Sources:.[11]

Investigational Studies and Future Directions

While Tisotumab vedotin has secured its place as a monotherapy for recurrent or metastatic cervical cancer, ongoing research aims to expand its utility to other malignancies and explore its potential in combination regimens. Early-phase safety studies have already included patients with other TF-expressing solid tumors, such as bladder cancer [47], and investigations in ovarian, lung, colorectal, and pancreatic cancers are underway, reflecting the broad potential of targeting TF.[3]

The innovaTV 205/GOG-3024/ENGOT-cx8 trial (NCT03786081) is a key Phase 1b/2 study evaluating Tisotumab vedotin in combination with other standard anticancer agents.[32] The results from this study have shown encouraging antitumor activity with manageable safety profiles, pointing toward future therapeutic strategies:

• Combination with Pembrolizumab (Anti-PD-1 Immunotherapy): In the first-line setting for recurrent or metastatic cervical cancer, the combination of Tisotumab vedotin and pembrolizumab yielded an ORR of 40.6%. In the second- or third-line setting, the ORR was 35.3%.[48]
• Combination with Carboplatin (Chemotherapy): As a first-line treatment, the combination with carboplatin produced a particularly high ORR of 54.5%.[48]

The clinical development pathway of Tisotumab vedotin illustrates a logical and strategic progression common in modern oncology drug development. The initial step was to establish robust single-agent activity in a refractory patient population with high unmet need, as accomplished in the innovaTV 204 and 301 trials.[6] This is an efficient route to initial regulatory approval. However, the therapeutic landscape for cervical cancer is rapidly evolving, with the standard of care for first-line treatment now incorporating immunotherapy (pembrolizumab) with chemotherapy, with or without bevacizumab.[10] For a new agent to maintain and expand its clinical relevance, it must demonstrate that it can be safely and effectively integrated into these new, more complex first-line regimens. The innovaTV 205 trial is a direct and strategic response to this evolution.[48] The promising response rates seen in the combination cohorts, especially with carboplatin and pembrolizumab, suggest a strong potential for synergy. This positions Tisotumab vedotin not just as a second-line monotherapy but as a potential cornerstone of future first-line combination therapies, representing the next frontier for its clinical application.

Safety Profile and Risk Management

The clinical use of Tisotumab vedotin is associated with a distinct and manageable safety profile, which is dominated by a high incidence of ocular toxicity. This requires a proactive and specialized approach to patient monitoring and management. While other adverse events are consistent with those expected from an MMAE-containing ADC, the ocular effects are a unique and defining feature of this therapy.

Boxed Warning: Ocular Toxicity

The most significant safety concern associated with Tisotumab vedotin is the risk of ocular adverse reactions, which has led the U.S. FDA to issue a Boxed Warning—its most stringent safety labeling requirement.[1] Ocular toxicities are very common, occurring in up to 60% of patients treated with the drug across clinical trials.[1]

The clinical presentation of these toxicities primarily involves the anterior surface of the eye. The most frequently reported events include:

• Conjunctivitis (inflammation of the conjunctiva), occurring in up to 40% of patients.[1]
• Dry eye (keratoconjunctivitis sicca), occurring in up to 29% of patients.[1]
• Keratitis or keratopathy (inflammation or damage to the cornea), occurring in up to 21% of patients.[1]
• Blepharitis (eyelid inflammation).[1]

These conditions can lead to symptoms such as eye redness, irritation, pain, blurred vision, and in severe cases, can progress to corneal ulceration and severe vision loss.[7]

Due to the frequency and potential severity of these events, a mandatory and comprehensive Risk Evaluation and Mitigation Strategy (REMS) focused on eye care is required for every patient receiving Tisotumab vedotin. This proactive management plan includes:

• Ophthalmic Examinations: A baseline ophthalmic examination by an eye care specialist, including visual acuity testing and a slit lamp exam, is required before initiating therapy. This examination must be repeated prior to each of the first nine treatment cycles, and as clinically indicated thereafter for any new or worsening symptoms.[8]
• Prophylactic Eye Drop Regimen: Patients are prescribed a specific regimen of eye drops to mitigate the risk of ocular toxicity.

1. Topical Corticosteroid Drops: To reduce inflammation, one drop is administered in each eye before each infusion, and this is continued three times daily for the 72 hours following the infusion.[8]
2. Topical Ocular Vasoconstrictor Drops: To reduce local drug delivery to the eye, these drops are administered in each eye immediately before the start of each infusion.[8]
3. Topical Lubricating Drops: To combat dry eye, preservative-free lubricating drops are to be used throughout the duration of therapy and for 30 days after the final dose.[8]

• Cooling Eye Pads: During the 30-minute intravenous infusion, cooling eye pads must be applied over the patient's eyes to induce local vasoconstriction and further limit drug exposure to the ocular surface.[8]
• Contact Lens Avoidance: Patients must be counseled to avoid wearing contact lenses for the entire duration of their treatment with Tisotumab vedotin, unless specifically advised otherwise by their eye care provider.[29]

Table 3: Grading and Management of Ocular Adverse Reactions

Ocular Adverse Reaction	First Occurrence	Second Occurrence
Confluent superficial keratitis, corneal epithelial defect, or $\geq$3 line loss in vision	Withhold dose until resolution/improvement. Resume at next lower dose level.	Permanently discontinue.
Conjunctival ulceration	Withhold dose until complete re-epithelialization. Resume at next lower dose level.	Permanently discontinue.

Management guidelines are based on the severity of the ocular event and are critical for patient safety. Sources:.[29]

Other Clinically Significant Adverse Reactions

Beyond the ocular toxicities, Tisotumab vedotin is associated with several other clinically important adverse reactions, many of which are characteristic of the MMAE payload.

• Peripheral Neuropathy (PN): This is a common adverse event, reported in 39% to 42% of patients.[1] The majority of cases are sensory in nature. Severe (Grade 3) PN occurs in approximately 6% to 8% of patients.[38] This toxicity is a known class effect of auristatin-based payloads like MMAE, which disrupt microtubule function in neurons, essential for axonal transport and maintenance.[4]
• Hemorrhage: Bleeding events are very common, occurring in about 60% of patients.[1] The vast majority of these events are low-grade (Grade 1 or 2) epistaxis (nosebleeds).[1] However, more severe hemorrhage can occur, and any bleeding in the central nervous system (CNS) or lungs necessitates permanent discontinuation of the drug.[29]
• Pneumonitis: Non-infectious inflammation of the lungs is a rare but serious and potentially life-threatening adverse event associated with MMAE-containing ADCs.[1] Patients should be monitored for new or worsening pulmonary symptoms.
• Severe Cutaneous Adverse Reactions (SCAR): Rare but potentially fatal skin reactions, including Stevens-Johnson syndrome (SJS), have been reported.[4]
• Most Common Adverse Reactions: In the pivotal innovaTV 301 trial, the most common adverse reactions (occurring in $\geq 25\%$ of patients) were decreased hemoglobin (anemia), peripheral neuropathy, conjunctival adverse reactions, elevated liver enzymes (AST and ALT), nausea, fatigue, epistaxis, and alopecia (hair loss).[6]

Management of Adverse Events: Dose Modifications and Discontinuation Criteria

To manage treatment-related toxicities, a standardized dose modification protocol is essential. The prescribing information provides a clear dose reduction schedule and specific criteria for withholding or discontinuing therapy based on the type and severity of the adverse reaction.[29]

The recommended dose reduction schedule is as follows:

• Starting Dose: 2.0 mg/kg (maximum 200 mg)
• First Dose Reduction: 1.3 mg/kg (maximum 130 mg)
• Second Dose Reduction: 0.9 mg/kg (maximum 90 mg)

If a patient is unable to tolerate the 0.9 mg/kg dose level, Tisotumab vedotin must be permanently discontinued.[29] Specific management guidelines for key non-ocular toxicities are outlined to ensure patient safety.

Table 4: Recommended Dose Modifications for Key Non-Ocular Adverse Reactions

Adverse Reaction	Grade	Recommended Action
Peripheral Neuropathy	Grade 2	Withhold until $\leq$Grade 1. Resume at next lower dose.
	Grade 3 or 4	Permanently discontinue.
Hemorrhage (Pulmonary/CNS)	Any Grade	Permanently discontinue.
Hemorrhage (Other)	Grade 2	Withhold until resolved. Resume at same dose.
	Grade 3 (1st occurrence)	Withhold until resolved. Resume at same dose.
	Grade 3 (2nd occurrence) or Grade 4	Permanently discontinue.
Pneumonitis	Grade 2	Withhold until $\leq$Grade 1. Consider resuming at next lower dose.
	Grade 3 or 4	Permanently discontinue.
Severe Cutaneous Reactions (incl. SJS)	Suspected (Any Grade)	Immediately withhold.
	Confirmed Grade 3 or 4	Permanently discontinue.

Management guidelines are based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading. Sources:.[29]

Regulatory Status and Prescribing Information

Global Regulatory Approvals

Tisotumab vedotin has achieved marketing authorization in several major global markets based on the strength of its clinical trial data, particularly the confirmatory results from the innovaTV 301 study.

• United States (Food and Drug Administration - FDA):
• Accelerated Approval: The FDA initially granted Accelerated Approval on September 20, 2021. This decision was based on the promising ORR and DOR data from the single-arm innovaTV 204 trial and was facilitated by a Priority Review designation.[1]
• Traditional (Full) Approval: Following the successful outcome of the innovaTV 301 trial, which demonstrated a significant overall survival benefit, the FDA granted full approval on April 29, 2024, converting the accelerated status and solidifying the drug's indication.[1]
• European Union (European Medicines Agency - EMA):
• The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization in January 2025.[1]
• The European Commission subsequently granted full marketing authorization for Tivdak on March 28-31, 2025, for the same indication as in the U.S..[1]
• Other Regions:
• Japan: The Ministry of Health, Labour, and Welfare (MHLW) approved Tisotumab vedotin in March 2025, making it the first ADC approved for cervical cancer in the country.[37]
• Hong Kong: The Department of Health granted approval in September 2025.[33]
• Australia (Therapeutic Goods Administration - TGA):
• As of the latest available information, Tisotumab vedotin (Tivdak) has not been registered on the Australian Register of Therapeutic Goods (ARTG).[55] Comprehensive searches of the TGA's public databases and related government documents did not yield evidence of an application or approval for this medication in Australia.[7] This marks a notable divergence in its global regulatory status compared to other major markets.

Dosing, Administration, and Patient Counseling

The safe and effective use of Tisotumab vedotin requires strict adherence to dosing, administration, and patient counseling guidelines.

• Recommended Dosage and Administration:
• The standard dose is 2 mg/kg, administered as a 30-minute intravenous infusion every three weeks.[4]
• For patients weighing 100 kg or more, the dose is capped at a maximum of 200 mg to mitigate exposure-related toxicity.[4]
• Treatment is continued until disease progression or the development of unacceptable toxicity.[8]
• Preparation: The lyophilized 40 mg vial must be reconstituted with 4 mL of Sterile Water for Injection. The calculated dose is then withdrawn and further diluted in a compatible infusion bag (5% Dextrose, 0.9% Sodium Chloride, or Lactated Ringer's) to a final concentration between 0.7 mg/mL and 2.4 mg/mL. The infusion must be administered through an intravenous line equipped with a 0.2 µm in-line filter.[53]
• Key Patient Counseling Points:
• Embryo-Fetal Toxicity: Tisotumab vedotin can cause harm to a developing fetus.[4] Females of reproductive potential must be tested for pregnancy before starting treatment and must be counseled to use effective contraception during therapy and for at least 2 months after the final dose. Males with female partners of reproductive potential should be advised to use effective contraception during treatment and for 4 months following the last dose.[52]
• Lactation: It is not known whether Tisotumab vedotin or its metabolites are excreted in human milk. Due to the potential for serious adverse reactions in a breastfed infant, patients should be advised not to breastfeed during treatment and for at least 3 weeks after their last dose.[7]
• Fertility: The drug may impair fertility in both females and males. Patients should be counseled on this potential risk.[52]
• Ocular Toxicity: Patients must be thoroughly educated on the signs and symptoms of ocular toxicity and the critical importance of adhering to the mandatory eye care regimen.

Role in Therapy and Clinical Guidelines

Placement in the Treatment Algorithm for Cervical Cancer

The positive results of the innovaTV 301 trial have firmly established Tisotumab vedotin as a new standard of care in the therapeutic algorithm for advanced cervical cancer.[8] It is indicated for patients with recurrent or metastatic disease whose cancer has progressed after receiving first-line, platinum-based chemotherapy.[8] Prior to its approval, the primary option in this second-line setting was single-agent chemotherapy, which offered limited benefit. Tisotumab vedotin is the first agent to demonstrate a statistically significant overall survival advantage over this comparator group.[11]

A crucial aspect of its clinical utility is its efficacy in the modern patient population. The innovaTV 301 trial enrolled patients reflective of current practice, including those who had previously received bevacizumab and/or anti-PD-(L)1 immunotherapy as part of their first-line treatment.[11] The survival benefit of Tisotumab vedotin was maintained in these subgroups, confirming its effectiveness in patients who have already been exposed to the latest first-line therapies and underscoring its role as a vital subsequent treatment option.[41]

NCCN and ESMO Guideline Recommendations

Leading oncology guideline organizations have recognized the practice-changing impact of Tisotumab vedotin, incorporating it into their formal recommendations for the management of cervical cancer.

• National Comprehensive Cancer Network (NCCN):
• The NCCN, whose guidelines are a key determinant of cancer care standards in the United States, has strongly endorsed Tisotumab vedotin. In its Clinical Practice Guidelines for Cervical Cancer (Version 4.2024/4.2025), Tisotumab vedotin is listed as a Category 1, Preferred option for second-line or subsequent therapy in the setting of recurrent or metastatic disease.[8]
• The designation of a treatment as "Category 1" by the NCCN signifies the highest level of evidence and uniform consensus among the guideline panel that the intervention is appropriate. This recommendation is based directly on the high-level evidence from the randomized, controlled innovaTV 301 trial. The additional designation of "Preferred" elevates Tisotumab vedotin above other available options in this setting, indicating that the NCCN panel considers it to offer the optimal benefit-risk profile. This rapid and high-level endorsement following the release of the Phase 3 data solidifies its position as the new standard of care for this patient population in the United States.
• European Society for Medical Oncology (ESMO):
• The most recent comprehensive ESMO guidelines for cervical cancer were published in 2017, with an update in 2020.[66] These publications predate the availability of the pivotal innovaTV 301 data and the subsequent 2025 marketing authorization by the EMA.
• Consequently, the current published ESMO guidelines do not yet include a specific recommendation for Tisotumab vedotin. They establish the general framework for treating metastatic disease, which has historically been palliative chemotherapy.[67] However, given that the EMA's approval was based on the same robust survival data from innovaTV 301 that drove the NCCN recommendation, it is anticipated that Tisotumab vedotin will be formally integrated as a standard second-line treatment option in the next iteration of the ESMO guidelines.

Conclusion and Expert Synthesis

Tisotumab vedotin-tftv (Tivdak®) represents a landmark achievement and a paradigm shift in the management of recurrent or metastatic cervical cancer. As the first-in-class Tissue Factor-directed antibody-drug conjugate, it has definitively established a new standard of care for patients whose disease has progressed after first-line chemotherapy. Its approval was based on an exceptionally robust clinical development program, culminating in the innovaTV 301 trial, which demonstrated a statistically significant and clinically meaningful overall survival benefit over single-agent chemotherapy—a benchmark that had not been met by previous agents in this challenging clinical setting.

The success of Tisotumab vedotin is a testament to the sophistication of modern ADC engineering. The combination of a highly specific human monoclonal antibody targeting an overexpressed tumor antigen, a potent microtubule-disrupting payload, and an intelligently designed cleavable linker has been clinically validated, resulting in superior efficacy. This achievement not only provides a vital new therapy for women with advanced cervical cancer but also validates Tissue Factor as a legitimate and druggable target in solid tumor oncology, paving the way for further research and development.

This profound efficacy, however, is intrinsically linked to a unique and demanding safety profile. The on-target, off-tumor activity of the drug results in a high incidence of ocular toxicity, a direct consequence of its mechanism of action. This necessitates a fundamental change in patient management, requiring a proactive, multidisciplinary approach that integrates diligent ophthalmologic monitoring with oncologic care. The mandatory and comprehensive eye care regimen is not an ancillary measure but a core component of the therapy itself, critical for mitigating risk and enabling patients to realize the drug's life-extending benefits.

In conclusion, Tisotumab vedotin offers a crucial and effective new weapon in the oncologic armamentarium against advanced cervical cancer, providing tangible hope by extending survival. Its therapeutic value is unequivocal. However, its optimal use demands a high degree of clinical vigilance, institutional preparedness, and patient education to proactively manage its distinct toxicities. The ongoing investigations into combination strategies and its activity in other TF-expressing tumors promise to further expand the role of this important therapeutic agent, potentially benefiting a wider range of cancer patients in the future.

Works cited

1. Tisotumab vedotin - Wikipedia, accessed October 20, 2025, https://en.wikipedia.org/wiki/Tisotumab_vedotin
2. Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer, accessed October 20, 2025, https://ir.genmab.com/news-releases/news-release-details/genmab-and-seagen-announce-fda-accelerated-approval-tivdaktm/
3. Tisotumab Vedotin - PubChem, accessed October 20, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tisotumab-Vedotin
4. Tisotumab Vedotin - LiverTox - NCBI Bookshelf, accessed October 20, 2025, https://www.ncbi.nlm.nih.gov/books/NBK598988/
5. Tisotumab vedotin (CAS 1418731-10-8) | Antibody-Drug Conjugates (ADCs), accessed October 20, 2025, https://adc.bocsci.com/product/tisotumab-vedotin-cas-1418731-10-8-426284.html
6. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer, accessed October 20, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
7. Tivdak® (tisotumab vedotin-tftv) | Official Patient Site, accessed October 20, 2025, https://www.tivdak.com/
8. Tivdak® (tisotumab vedotin-tftv intravenous infusion - Viva Health, accessed October 20, 2025, https://www.vivahealth.com/files/medicare/policies/tivdak-tisotumab-vedotin-tftv
9. Tivdak | European Medicines Agency (EMA), accessed October 20, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/tivdak
10. Current Management of Locally Advanced and Metastatic Cervical Cancer in the United States | JCO Oncology Practice - ASCO Publications, accessed October 20, 2025, https://ascopubs.org/doi/10.1200/OP.21.00795
11. FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer, accessed October 20, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
12. FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer | OncLive, accessed October 20, 2025, https://www.onclive.com/view/fda-approves-tisotumab-vedotin-for-recurrent-or-metastatic-cervical-cancer
13. TIVDAK® (tisotumab vedotin-tftv) Description | Pfizer Medical - US, accessed October 20, 2025, https://www.pfizermedical.com/tivdak/description
14. Tisotumab vedotin | BroadPharm, accessed October 20, 2025, https://broadpharm.com/product/BP-50208
15. Tisotumab vedotin | Antibody-Drug Conjugate | MedChemExpress, accessed October 20, 2025, https://www.medchemexpress.com/tisotumab-vedotin.html
16. What is the mechanism of action of Tisotumab Vedotin-tftv? - Patsnap Synapse, accessed October 20, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-action-of-tisotumab-vedotin-tftv
17. The potency of a cytotoxic agent combined with the specificity of an antibody 1,2 - Tivdak® (tisotumab vedotin-tftv), accessed October 20, 2025, https://www.tivdakhcp.com/about-tivdak/
18. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors - PMC, accessed October 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9574719/
19. The Vedotin Antibody–Drug Conjugate Payload Drives Platform-Based Nonclinical Safety and Pharmacokinetic Profiles - AACR Journals, accessed October 20, 2025, https://aacrjournals.org/mct/article/23/10/1483/748612/The-Vedotin-Antibody-Drug-Conjugate-Payload-Drives
20. pubchem.ncbi.nlm.nih.gov, accessed October 20, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Tisotumab-Vedotin#:~:text=Tisotumab%20Vedotin%20is%20an%20antibody,microtubule%20disrupting%20agent%2C%20with%20potential
21. www.ncbi.nlm.nih.gov, accessed October 20, 2025, https://www.ncbi.nlm.nih.gov/books/NBK598988/#:~:text=When%20tisotumab%20binds%20to%20TF,joins%20the%20antibody%20and%20cytotoxin.
22. Tisotumab Vedotin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf, accessed October 20, 2025, https://www.ncbi.nlm.nih.gov/books/NBK592198/
23. Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy - Assay Genie, accessed October 20, 2025, https://www.assaygenie.com/blog/tisotumab-vedotin-a-breakthrough-in-targeted-cancer-therapy/
24. What is the mechanism of Tisotumab Vedotin-tftv? - Patsnap Synapse, accessed October 20, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-tisotumab-vedotin-tftv
25. Tisotumab vedotin for the treatment of cervical carcinoma, accessed October 20, 2025, https://sjharchives.sclhealth.org/digital/api/collection/p17090coll25/id/291/download
26. TIVDAK® (tisotumab vedotin-tftv) Clinical Pharmacology | Pfizer Medical - US, accessed October 20, 2025, https://www.pfizermedical.com/tivdak/clinical-pharmacology
27. Tisotumab vedotin: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 20, 2025, https://go.drugbank.com/drugs/DB16732
28. Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors - ResearchGate, accessed October 20, 2025, https://www.researchgate.net/publication/362525745_Population_pharmacokinetic_analysis_for_tisotumab_vedotin_in_patients_with_locally_advanced_andor_metastatic_solid_tumors
29. Tivdak (tisotumab vedotin) dosing, indications, interactions, adverse effects, and more, accessed October 20, 2025, https://reference.medscape.com/drug/tivdak-tisotumab-vedotin-4000217
30. Study Details | NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | ClinicalTrials.gov, accessed October 20, 2025, https://www.clinicaltrials.gov/study/NCT03438396
31. Tisotumab vedotin approved by FDA for cervical cancer - The Antibody Society, accessed October 20, 2025, https://www.antibodysociety.org/antibody-therapeutic/tisotumab-vedotin-approved-by-fda-for-cervical-cancer/
32. Tisotumab vedotin in recurrent or metastatic cervical cancer - PubMed, accessed October 20, 2025, https://pubmed.ncbi.nlm.nih.gov/36842202/
33. Tisotumab Vedotin Sees Positive Topline Results in the Phase 2 InnovaTV 204 Trial, accessed October 20, 2025, https://www.cancernetwork.com/view/tisotumab-vedotin-sees-positive-topline-results-in-the-phase-2-innovatv-204-trial
34. Tisotumab Vedotin Shows Promise in Recurrent/Metastatic Cervical Cancer, accessed October 20, 2025, https://www.targetedonc.com/view/tisotumab-vedotin-shows-promise-in-recurrent-metastatic-cervical-cancer
35. Tisotumab Vedotin: First Approval - PubMed, accessed October 20, 2025, https://pubmed.ncbi.nlm.nih.gov/34748188/
36. In Recurrent Cervical Cancer, Tisotumab Vedotin-tftv Improves Overall Survival in Phase III Trial - The ASCO Post, accessed October 20, 2025, https://ascopost.com/issues/november-25-2023/in-recurrent-cervical-cancer-tisotumab-vedotin-tftv-improves-overall-survival-in-phase-iii-trial/
37. TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer - Genmab News, accessed October 20, 2025, https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-european-commission/
38. TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial - Investor Overview, accessed October 20, 2025, https://ir.zailaboratory.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-tftv-significantly-prolonged-overall/
39. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer - PubMed, accessed October 20, 2025, https://pubmed.ncbi.nlm.nih.gov/38959480/
40. Tisotumab Vedotin Approved in Hong Kong for Recurrent or Metastatic Cervical Cancer, accessed October 20, 2025, https://www.onclive.com/view/tisotumab-vedotin-approved-in-hong-kong-for-recurrent-or-metastatic-cervical-cancer
41. Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy than Chemotherapy in Patients with Recurrent Cervical Cancer | ESMO, accessed October 20, 2025, https://www.esmo.org/oncology-news/second-or-third-line-treatment-with-tisotumab-vedotin-results-in-greater-efficacy-than-chemotherapy-in-patients-with-recurrent-cervical-cancer
42. Tisotumab Vedotin as Second or Third-Line Therapy for Recurrent Cervical Cancer, accessed October 20, 2025, https://www.2minutemedicine.com/tisotumab-vedotin-as-second-or-third-line-therapy-for-recurrent-cervical-cancer/
43. Tisotumab Vedotin Continues to Show Survival Benefits in Recurrent Cervical Cancer, accessed October 20, 2025, https://www.targetedonc.com/view/tisotumab-vedotin-continues-to-show-survival-benefits-in-recurrent-cervical-cancer
44. EMA Validates Tisotumab Vedotin Marketing Application in Cervical Cancer, accessed October 20, 2025, https://www.cancernetwork.com/view/ema-validates-tisotumab-vedotin-marketing-application-in-cervical-cancer
45. Tisotumab Vedotin Gains Full FDA Approval in Advanced Cervical Cancer, accessed October 20, 2025, https://www.targetedonc.com/view/tisotumab-vedotin-gains-full-fda-approval-in-advanced-cervical-cancer
46. TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer | Nasdaq, accessed October 20, 2025, https://www.nasdaq.com/press-release/tivdakr-tisotumab-vedotin-approved-european-commission-previously-treated-recurrent
47. Cancer of Bladder Completed Phase 1 / 2 Trials for Tisotumab vedotin (DB16732), accessed October 20, 2025, https://go.drugbank.com/indications/DBCOND0087984/clinical_trials/DB16732?phase=1%2C2&status=completed
48. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study - PubMed, accessed October 20, 2025, https://pubmed.ncbi.nlm.nih.gov/37651655/
49. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study - ASCO Publications, accessed October 20, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.23.00720
50. Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic - PURE.EUR.NL., accessed October 20, 2025, https://pure.eur.nl/files/123818933/vergote-et-al-2023-tisotumab-vedotin-in-combination-with-carboplatin-pembrolizumab-or-bevacizumab-in-recurrent-or.pdf
51. Tivdak® (tisotumab vedotin-tftv) | For Healthcare Professionals, accessed October 20, 2025, https://www.tivdakhcp.com/
52. MEDICATION GUIDE TIVDAK (TIV-dack) (tisotumab vedotin-tftv) for injection, for intravenous use What is the most important inform, accessed October 20, 2025, https://webfiles.pfizer.com/Tivdak_Medication_Guide_Master.pdf
53. TIVDAK® (tisotumab vedotin-tftv) Dosage and Administration | Pfizer Medical - US, accessed October 20, 2025, https://www.pfizermedical.com/tivdak/dosage-admin
54. TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy - Genmab News, accessed October 20, 2025, https://ir.genmab.com/news-releases/news-release-details/tivdakr-tisotumab-vedotin-approved-japan-ministry-health-labour/
55. HTA Policy and Methods Review – Emerging health technologies [Word, accessed October 20, 2025, https://www.health.gov.au/sites/default/files/2024-07/hta-policy-and-methods-review-emerging-health-technologies.docx
56. Padcev | Therapeutic Goods Administration (TGA), accessed October 20, 2025, https://www.tga.gov.au/resources/auspmd/padcev
57. Australian Register of Therapeutic Goods (ARTG), accessed October 20, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
58. Australian TGA Sponsor - MedEnvoy Global, accessed October 20, 2025, https://medenvoyglobal.com/in-country-representation/australian-tga-sponsor/
59. ARTG Search Visualisation Tool - the Regulatory and Compliance Portal., accessed October 20, 2025, https://compliance.health.gov.au/artg/
60. Therapeutic Goods Administration (TGA) | Australian Government Department of Health, Disability and Ageing, accessed October 20, 2025, https://www.tga.gov.au/
61. Medicines | Therapeutic Goods Administration (TGA), accessed October 20, 2025, https://www.tga.gov.au/products/medicines
62. tisotumab vedotin | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 20, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11719
63. Search for tisotumab vedotin - Clinical Trials register, accessed October 20, 2025, https://www.clinicaltrialsregister.eu/ctr-search/search?query=tisotumab+vedotin
64. Therapeutic Goods Administration (TGA) - Digital Health Developer Portal, accessed October 20, 2025, https://developer.digitalhealth.gov.au/standards/organisation/therapeutic-goods-administration-tga
65. TGA – Therapeutic Goods Administration - Healthdirect, accessed October 20, 2025, https://www.healthdirect.gov.au/partners/tga-therapeutic-goods-administration
66. ESMO Clinical Practice Guideline: Cervical Cancer, accessed October 20, 2025, https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-cervical-cancer
67. Both complete response and long-term survival after combination therapy with toripalimab in a patient with meta-oligometastases cervical cancer: a case report - PMC - PubMed Central, accessed October 20, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12009880/